Overview

Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Pirfenidone as anti-fibrosis drug developed in recent years demonstrated the potential anti- fibrotic effect, but so far there were no domestic studies about pirfenidone's efficacy and safety evaluation in china. The aim of this study was to evaluate the efficacy and safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) through the observation of a large sample of clinical cases.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Collaborator:
Nanjing Chia-tai Tianqing Pharmaceutical
Treatments:
Pirfenidone